Denosumab and bisphosphonates in clinically overt osteoporosis, what can happen?

Denosumab is a medicine used to treat osteoporosis in postmenopausal women and in men with osteoporosis associated with treatment with cancer hormones. It is a monoclonal antibody that acts on the skeletal system, inhibiting bone breakdown and increasing bone mineral density. Bisphosphonates are another group of drugs used to treat osteoporosis. They inhibit the activity of osteoclasts, which reduces bone breakdown and helps maintain bone mineral density. Like all medications, both denosumab and bisphosphonates may have some risks and side effects. With denosumab, side effects such as back pain, arthralgia, pain in extremity, muscle cramps, headache, abdominal pain, nausea, fatigue, respiratory infections, conjunctivitis, alopecia, skin rash, skin sensitivity and skin reactions at the injection site may occur. With bisphosphonates, side effects such as muscle and joint pain, nausea, heartburn, dyspepsia, diarrhea, constipation, headache, muscle weakness, gastroesophageal reflux, gastrointestinal ulcers, allergic reactions and, less commonly, inflammation of the jaw (osteonecrosis of the jaw) may occur. It is important that you discuss any concerns or concerns with your doctor before starting any of these medicines. Only a doctor will be able to assess your current health and adapt the therapy to your individual needs. If you are unable to get to your primary care doctor, the GdziePoLek.pl service also allows you to obtain a teleconsultation with a doctor: https://www.gdziepolek.pl/telekonsultacja I enclose materials that may be of interest: https://www.gdziepolek.pl/artykuly/osteoporoza-jak-zapobiegac-i-jak-leczyc